2bPrecise delivers transformative point-of-care solutions that serve as the foundation for scalable precision medicine success.

Precision medicine is rewriting the rules of health care. And 2bPrecise is rewriting the rules of precision medicine. Representing decades of deep clinical knowledge and award-winning technology, our 2bPrecise platform heavy-lifts vast amounts of the data you need, then simplifies, condenses and extracts it. The result? Integrated, actionable genomic information delivered directly into your workflow and harmonized with existing patient data – in any EHR. Plus, semantically stored, research-ready data that can be accessed and acted upon for later study – as science evolves. That’s a powerful set of clinical decision-making tools, in your hands – at the point of care.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.